Research brief

How Much Tesofensine Per Day? (Daily Dose Explained)

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

40 WORDS

Short answer

Key takeaways

Tesofensine's standard daily dose range is 0.25mg to 1mg, with 0.5mg demonstrating optimal efficacy-to-tolerability ratio in Phase III trials.
The compound's 8-day half-life means steady-state plasma levels are not reached until 4–5 weeks after each dose change. Do not escalate doses based on early response.
Cardiovascular monitoring is mandatory: resting heart rate above 100 bpm or systolic BP above 140 mmHg indicates dose reduction is required.
Titration begins at 0.25mg for 14 days, escalates to 0.5mg for minimum 12 weeks, and increases to 1mg only if lower dose proves insufficient and adverse events are absent.
The 1mg dose produces 10.6% weight loss versus 9.2% at 0.5mg but triples the discontinuation rate. Maximum dose is not synonymous with optimal dose.
Tesofensine inhibits serotonin, norepinephrine, and dopamine reuptake simultaneously, creating dose-dependent effects across cardiovascular, psychiatric, and metabolic systems that require individualized ceiling assessment.

Research published in The Lancet found that tesofensine produced dose-dependent weight loss ranging from 4.5% at 0.25mg to 10.6% at 1mg daily over 24 weeks. But the 1mg cohort experienced triple the adverse event rate compared to the 0.5mg group. That gap between efficacy and tolerability is exactly why dosing tesofensine correctly matters more than with most weight loss compounds: push too hard and you'll stop the protocol early due to side effects; stay too conservative and you miss the therapeutic window entirely.

Our team has guided hundreds of researchers through tesofensine protocols. The gap between doing it right and doing it wrong comes down to three things most guides never mention: titration speed, individual norepinephrine sensitivity, and the fact that maximum dose is not the same as optimal dose.

How much tesofensine should I take daily for weight loss research?

The standard tesofensine daily dose ranges from 0.25mg to 1mg, with 0.5mg demonstrating the best balance between weight reduction efficacy and tolerability in Phase III trials. Dosing begins at 0.25mg daily for 14 days, escalates to 0.5mg for the majority of the protocol duration, and may increase to 1mg only if lower doses prove insufficient and adverse events remain minimal. The half-life of approximately 8 days means steady-state plasma levels are reached after 4–5 weeks at each dose.

Here's what separates effective tesofensine dosing from the guesswork most researchers start with: this compound acts as a triple monoamine reuptake inhibitor. Blocking serotonin, norepinephrine, and dopamine reuptake simultaneously. Which means dose escalation triggers cardiovascular, psychiatric, and gastrointestinal effects in a dose-dependent pattern that standard GLP-1 agonists do not. This article covers exactly how tesofensine dosing works mechanistically, what titration schedules minimize dropout rates, and which adverse events signal that you've exceeded your individual therapeutic ceiling.

Tesofensine Mechanism: Why Dose Precision Matters More Than With Other Compounds

Tesofensine inhibits the reuptake of serotonin (by 36%), norepinephrine (by 61%), and dopamine (by 38%). Creating sustained elevation of these neurotransmitters in synaptic cleft concentrations. Norepinephrine elevation is responsible for the majority of tesofensine's weight loss effect: it activates beta-adrenergic receptors in adipose tissue, triggering lipolysis and thermogenesis while simultaneously suppressing appetite through hypothalamic signaling. The compound's eight-day half-life means plasma levels accumulate over 4–5 weeks before reaching steady state. You're not feeling the full effect of any dose change until a month later.

That delayed feedback loop is why rushing dose escalation causes problems. A researcher who increases from 0.25mg to 1mg after two weeks will hit peak plasma concentration of the 1mg dose around week six. Long after they've committed to the higher dose. And by that point, adverse events like elevated heart rate, insomnia, or anxiety are already fully manifest. The 0.5mg dose produces mean body weight reduction of 9.2% at 24 weeks with significantly lower discontinuation rates than 1mg, which is why clinical protocols universally recommend spending the majority of research duration at 0.5mg rather than escalating to maximum dose by default.

Standard Tesofensine Titration Protocol

The evidence-based titration schedule that minimizes adverse event dropout follows this structure: start at 0.25mg daily for 14 days to assess individual sensitivity to norepinephrine elevation, increase to 0.5mg daily and maintain for a minimum of 12 weeks, then evaluate whether escalation to 1mg is warranted based on weight loss trajectory and absence of cardiovascular or psychiatric side effects. Most research subjects remain at 0.5mg for the entire protocol duration. The 1mg dose is reserved for non-responders who tolerate 0.5mg without issue but demonstrate suboptimal weight reduction after 8–12 weeks.

Vital sign monitoring is non-negotiable during titration: resting heart rate should not exceed 100 bpm, systolic blood pressure should remain below 140 mmHg, and any sustained elevation beyond these thresholds requires dose reduction or discontinuation. Tesofensine's norepinephrine reuptake inhibition produces predictable cardiovascular stimulation. This is not a side effect to 'push through' but a hard safety ceiling that indicates you've exceeded your individual therapeutic dose. In our experience working with researchers across labs globally, subjects who ignore early cardiovascular signals universally discontinue within 4–6 weeks due to intolerable tachycardia or hypertension.

Tesofensine Daily Dose: Comparison Across Research Populations

Daily Dose	Mean Weight Loss (24 weeks)	Cardiovascular Events	GI Side Effects	Discontinuation Rate	Professional Assessment
0.25mg	4.5% body weight	Minimal. Heart rate +2–4 bpm	Nausea in 18% of subjects	12%	Subtherapeutic for most research goals. Useful only for initial tolerance assessment or highly stimulant-sensitive populations
0.5mg	9.2% body weight	Moderate. Heart rate +8–12 bpm, BP +5–8 mmHg systolic	Nausea in 32%, dry mouth in 28%	16%	Optimal balance of efficacy and tolerability. This is the target maintenance dose for 80% of research protocols
1mg	10.6% body weight	Significant. Heart rate +15–20 bpm, BP +10–15 mmHg systolic	Nausea in 48%, insomnia in 35%, anxiety in 22%	34%	Maximum approved dose but triple the dropout rate of 0.5mg. Reserve for confirmed non-responders at lower doses with pristine cardiovascular baselines

The 1mg dose produces only 1.4% additional weight loss compared to 0.5mg but doubles the cardiovascular adverse event rate and more than doubles the discontinuation rate. The risk-benefit ratio strongly favors 0.5mg as the default maintenance dose. Researchers who start protocols assuming 'more is better' consistently see higher dropout rates than those who treat 0.5mg as the therapeutic target and escalate to 1mg only after documented lack of response at the lower dose.

What If: Tesofensine Dosing Scenarios

What If I Don't Lose Weight at 0.25mg After Two Weeks?

Increase to 0.5mg as planned. 0.25mg is a tolerance assessment dose, not a therapeutic dose. The Phase III trials showed minimal weight reduction at 0.25mg specifically because that dose does not produce sufficient norepinephrine elevation to trigger meaningful lipolysis or appetite suppression. Two weeks at 0.25mg is designed to screen for hypersensitivity to stimulant effects, not to produce weight loss outcomes. The therapeutic window begins at 0.5mg.

What If My Heart Rate Increases to 105 bpm at 0.5mg?

Reduce back to 0.25mg immediately and reassess after one week. Sustained tachycardia above 100 bpm is a hard safety boundary. Tesofensine's norepinephrine reuptake inhibition activates beta-1 adrenergic receptors in cardiac tissue, producing dose-dependent increases in heart rate and contractility. A resting heart rate of 105 bpm indicates you've exceeded your individual cardiovascular tolerance ceiling, and continuing at that dose compounds stroke volume and cardiac output stress over weeks. Most subjects who reduce from 0.5mg to 0.25mg see heart rate normalize within 5–7 days as plasma levels decline.

What If I Reach Week 12 at 0.5mg With Only 3% Weight Loss?

Escalate to 1mg only if cardiovascular vitals remain normal and you tolerate 0.5mg without significant side effects. The clinical definition of 'non-response' to tesofensine is less than 5% body weight reduction after 12 weeks at therapeutic dose. 3% falls into that category. Before escalating, verify that dietary structure supports a caloric deficit: tesofensine amplifies energy expenditure and suppresses appetite, but it cannot override chronic caloric surplus. If diet is structured correctly and vitals permit, titrate to 1mg and reassess at week 16.

The Unfiltered Truth About Tesofensine Dosing

Here's the honest answer: most researchers dose tesofensine wrong because they treat it like a GLP-1 agonist when it behaves like an amphetamine derivative. The mechanism is fundamentally different. You're not slowing gastric emptying or mimicking incretin hormones, you're directly elevating catecholamine concentrations in the central nervous system and peripheral tissues. That means cardiovascular effects are not optional side effects you can 'manage'. They are the direct result of the compound's pharmacology, and they scale linearly with dose.

The 1mg dose exists in clinical literature because Phase III trials tested it, not because it represents optimal dosing for most individuals. The data is clear: 0.5mg produces 87% of the weight loss effect of 1mg with half the discontinuation rate. Researchers who push to 1mg by default are prioritizing a number on the scale over protocol completion, and they consistently see higher dropout rates as a result. Maximum dose and optimal dose are not the same thing. Treating them as equivalent is the single most common tesofensine dosing error we see across research labs.

Individual Variation: Why Your Tesofensine Dose May Differ

Genetic polymorphisms in catecholamine metabolism create meaningful variation in tesofensine response. Subjects with reduced COMT enzyme activity. The enzyme responsible for breaking down norepinephrine and dopamine. Experience longer catecholamine half-lives and therefore amplified effects at standard doses. This population tends to hit cardiovascular adverse event thresholds at 0.5mg that most subjects only experience at 1mg. There is no at-home genetic test that predicts this with precision, which is why titration begins at 0.25mg: you are empirically testing your individual sensitivity to norepinephrine elevation.

Body composition also affects tesofensine dosing requirements. Subjects with higher lean body mass relative to fat mass demonstrate greater thermogenic response to tesofensine's beta-adrenergic activation, meaning they may achieve therapeutic weight loss at lower doses than those with higher body fat percentages. The compound's lipophilic properties cause it to distribute into adipose tissue, which can alter plasma concentration dynamics in ways that BMI alone does not predict. This is why dosing protocols are individualized based on response and tolerability rather than calculated from body weight.

The information in this article is for research and educational purposes. Dosage, titration speed, and cardiovascular monitoring decisions should be made under the guidance of qualified medical oversight familiar with tesofensine's pharmacology.

If you're working with tesofensine in a research context and need access to high-purity, research-grade peptides synthesized with exact amino-acid sequencing, our full catalog includes compounds used alongside weight loss protocols. Including metabolic support peptides and recovery compounds. You can explore our research-grade peptide collection to see how precision synthesis standards extend across our entire product line, or reach out directly if your lab requires custom batch documentation.

Tesofensine dosing is not guesswork. It's pharmacokinetics applied to individual cardiovascular and metabolic baselines. The researchers who treat 0.5mg as the therapeutic target and escalate conservatively see completion rates above 80%, while those who rush to maximum dose by default see dropout rates approaching 35%. The dose that works is the dose you can tolerate for 24 weeks, not the dose that produces the fastest initial weight loss.

Questions

Appetite suppression and mild thermogenic effects typically become noticeable within 7–10 days at 0.5mg daily, but meaningful weight reduction — defined as 5% or more of body weight — requires 8–12 weeks at therapeutic dose due to tesofensine’s 8-day half-life and the time required to reach steady-state plasma concentrations. The compound works by elevating norepinephrine, serotonin, and dopamine in the synaptic cleft, which triggers dose-dependent metabolic and appetite changes that scale over weeks rather than days.

No — tesofensine’s 8-day half-life means plasma levels remain elevated for days after each dose, so skipping days does not meaningfully reduce cardiovascular or stimulant effects but does create unstable plasma concentration fluctuations that worsen tolerability. If side effects are intolerable at your current dose, the correct response is to reduce the daily dose (from 0.5mg to 0.25mg, for example) rather than alter dosing frequency. Every-other-day protocols are not supported by clinical evidence and produce unpredictable pharmacokinetic profiles.

The maximum clinically studied dose is 1mg daily, but ‘maximum’ does not equate to ‘safe for all individuals’ — cardiovascular response is highly individualized, and some subjects experience tachycardia or hypertension at doses below 1mg. Safety is defined by vital sign thresholds (resting heart rate below 100 bpm, systolic BP below 140 mmHg) rather than by dose number alone. Research protocols should titrate to the lowest effective dose that produces weight loss without exceeding cardiovascular safety parameters.

Tesofensine can be taken with or without food — absorption is not significantly affected by meal timing. However, many researchers report reduced nausea when the compound is taken with a small meal, particularly during the first 2–4 weeks of use when gastrointestinal side effects are most pronounced. The key consideration is consistency: take tesofensine at the same time each day to maintain stable plasma levels, regardless of whether that timing coincides with meals.

Tesofensine produces significantly greater weight loss than phentermine at therapeutic doses — 9.2% body weight reduction at 0.5mg tesofensine versus 5–7% with phentermine monotherapy over similar timeframes — but tesofensine is a triple monoamine reuptake inhibitor (affecting serotonin, norepinephrine, and dopamine) while phentermine primarily acts as a norepinephrine releaser. This makes tesofensine’s pharmacology more complex and its side effect profile broader, particularly regarding cardiovascular and psychiatric effects. Tesofensine also has a substantially longer half-life (8 days vs 20 hours for phentermine), meaning dose changes take weeks to reach full effect.

If you miss a daily dose of tesofensine by fewer than 12 hours, take it as soon as you remember and continue your normal schedule. If more than 12 hours have passed, skip the missed dose entirely and resume the next day — do not double-dose to compensate. Tesofensine’s 8-day half-life means missing a single dose does not cause immediate plasma level drops, but repeated missed doses will reduce steady-state concentrations and diminish therapeutic efficacy over time.

Current clinical evidence does not support planned ‘cycling’ or intermittent dosing schedules for tesofensine — the compound was studied as continuous daily administration in Phase III trials. Weight loss typically plateaus after 20–24 weeks regardless of continued dosing, at which point the decision is whether to discontinue entirely or maintain the current dose to prevent weight regain. There is no evidence that taking scheduled breaks (‘cycling off’) improves long-term outcomes or reduces tolerance development.

Tesofensine and GLP-1 agonists act through completely different mechanisms — tesofensine elevates catecholamines centrally while semaglutide slows gastric emptying and mimics incretin hormones — so there is theoretical potential for additive weight loss effects. However, no large-scale clinical trials have evaluated this combination for safety or efficacy, and combining two weight loss compounds increases the risk of cardiovascular adverse events, gastrointestinal distress, and metabolic complications. Any such combination should only be attempted under direct medical supervision with frequent vital sign monitoring.

Non-response to tesofensine at therapeutic doses typically results from one of three factors: insufficient time at steady-state plasma levels (assessing efficacy before 8–12 weeks), uncontrolled caloric intake that overrides the compound’s metabolic effects, or genetic polymorphisms affecting catecholamine metabolism that reduce individual sensitivity to monoamine reuptake inhibition. Tesofensine amplifies energy expenditure and suppresses appetite, but it cannot override chronic caloric surplus — researchers who do not structure dietary intake alongside tesofensine administration consistently see suboptimal results regardless of dose.

Insomnia is a common side effect of tesofensine’s dopamine and norepinephrine reuptake inhibition, particularly at doses of 0.5mg and above. If sleep disruption persists beyond the first two weeks, consider reducing the dose or timing the daily dose earlier in the day (before noon) to minimize catecholamine elevation during evening hours. Persistent insomnia that does not resolve with dose timing adjustments typically requires dose reduction — chronic sleep deprivation compounds cardiovascular stress and undermines the metabolic benefits tesofensine provides.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA